Andros Pharmaceuticals Co.,Ltd
6917.TWO
Price:
$26.1
Market Cap:
$1.22B
Andros Pharmaceuticals Co.,Ltd, a biopharmaceutical company, engages in developing novel drug delivery platform technologies. The company develops APC101, a fast-drying, film-forming, and meter-dosed spray, which is in Phase IIa clinical trial to treat pain associated with post-herpetic neuralgia; APC201, a novel dosage form of topical anesthetic that is in Phase I/II clinical trial for treatment of Osteoarthritis; and siRNA, an anti-sense oligonucleotide and DNA candidate. Its preclinical phase products are APC310 and APC501 for anesthesia to intravenous catheter placement and venipuncture; and APC401, a special emulsified solution for anesthesia of post-surgery pain. The company offers LAL...[Read more]
Industry
Biotechnology
IPO Date
2023-01-12
Stock Exchange
TWO
Ticker
6917.TWO
PE Ratio
[-13.05]
ROE
[-18.09%]
Current Ratio
[13.81]
Dividend Yield
[0%]
Enterprise Value
[1.20B]
Dividend History
The ROE as of December 2025 (TTM) for Andros Pharmaceuticals Co.,Ltd (6917.TWO) is -18.09%
According to Andros Pharmaceuticals Co.,Ltd’s latest financial reports and current stock price. The company's current ROE is -18.09%. This represents a change of -Infinity% compared to the average of 0% of the last 4 quarters.
Andros Pharmaceuticals Co.,Ltd (6917.TWO) Historical ROE (quarterly & annually)
How has 6917.TWO ROE performed in the past?
The mean historical ROE of Andros Pharmaceuticals Co.,Ltd over the last ten years is -23.81%. The current -18.09% ROE has changed -24.01% with respect to the historical average. Over the past ten years (40 quarters), 6917.TWO's ROE was at its highest in in the December 2022 quarter at 0%. The ROE was at its lowest in in the December 2022 quarter at 0%.
Average
-23.81%
Median
-17.30%
Minimum
-54.08%
Maximum
0%
Andros Pharmaceuticals Co.,Ltd (6917.TWO) ROE by Quarter and Year
Discovering the peaks and valleys of Andros Pharmaceuticals Co.,Ltd ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 37.26%
Maximum Annual ROE = 0%
Minimum Annual Increase = -Infinity%
Minimum Annual ROE = -54.08%
| Year | ROE | Change |
|---|---|---|
| 2024 | -19.86% | 37.26% |
| 2023 | -14.47% | -1.80% |
| 2022 | -14.73% | -72.76% |
| 2021 | -54.08% | 36.17% |
| 2020 | -39.72% | -Infinity% |
Andros Pharmaceuticals Co.,Ltd (6917.TWO) Average ROE
How has 6917.TWO ROE performed in the past?
The current ROE of Andros Pharmaceuticals Co.,Ltd (6917.TWO) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-16.35%
5-year avg
-28.57%
10-year avg
-23.81%
Andros Pharmaceuticals Co.,Ltd (6917.TWO) ROE vs. Peers
How is 6917.TWO’s ROE compared to its peers?
Andros Pharmaceuticals Co.,Ltd’s ROE is greater than SynCore Biotechnology Co.,Ltd (-18.31%), greater than Eusol Biotech Co.,Ltd. (-10.52%), greater than LAUNXP Biomedical Co., Ltd (-56.54%), greater than NatureWise Biotech & Medicals Corporation (-5.58%), greater than Bio Preventive Medicine Corp. (-24.73%), greater than Lukas Biomedical Inc. (-31.59%), less than TCI GENE Inc. (3.64%), greater than LabTurbo Biotech Corporation (-12.54%), less than BioLASCO Taiwan Co., Ltd. (11.19%), greater than General Biologicals Corporation (-110.52%),
| Company | ROE | Market cap |
|---|---|---|
| -18.31% | $905.50M | |
| -10.52% | $835.70M | |
| -56.54% | $1.10B | |
| -5.58% | $1.04B | |
| -24.73% | $1.14B | |
| -31.59% | $1.32B | |
| 3.64% | $984.26M | |
| -12.54% | $1.16B | |
| 11.19% | $813.18M | |
| -110.52% | $723.91M |
Build a custom stock screener for Andros Pharmaceuticals Co.,Ltd (6917.TWO) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Andros Pharmaceuticals Co.,Ltd using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Andros Pharmaceuticals Co.,Ltd (6917.TWO) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Andros Pharmaceuticals Co.,Ltd or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Andros Pharmaceuticals Co.,Ltd's ROE?
How is the ROE calculated for Andros Pharmaceuticals Co.,Ltd (6917.TWO)?
What is the highest ROE for Andros Pharmaceuticals Co.,Ltd (6917.TWO)?
What is the 3-year average ROE for Andros Pharmaceuticals Co.,Ltd (6917.TWO)?
What is the 5-year average ROE for Andros Pharmaceuticals Co.,Ltd (6917.TWO)?
How does the current ROE for Andros Pharmaceuticals Co.,Ltd (6917.TWO) compare to its historical average?